Newsroom
Sorted by: Latest
-
Reading Football Club Announces AI Partnership with Stelia, Powered by NVIDIA and Lenovo
LONDON--(BUSINESS WIRE)--UK's Reading Football Club partners with Stelia AI to establish AI Centre of Excellence, with accelerated compute infrastructure from NVIDIA & Lenovo...
-
Deutsche Bank AG UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- Commonwealth Bank of Australia Issue of EUR 400,000,000.00 Floating Rate Notes due December 2026 Series 6717 Tranche 1 MTN ISSUE NAME. Our Ref. MV2555 ISIN Code. XS3251563253 TOTAL INTEREST AMT. CURRENCY CODE. EUR DAY BASIS. Actual/360 (A004) NUM OF DAYS. 92 INTEREST RATE. 2.21587 PCT VALUE DATE. 12/06/2026 INTEREST PERIOD. 12/03/2026 TO 12/06/2026 EUR 2,265,111.56 POOL FACTOR. N/A...
-
Nebius expands in UK with more NVIDIA-powered infrastructure, more customers, and more cloud capabilities for agentic and enterprise AI
LONDON--(BUSINESS WIRE)--Nebius (Nasdaq: NBIS), the AI cloud company, today announced it is investing approximately £1.7 billion to build out capacity in the UK with three new deployments of NVIDIA infrastructure, as the company continues to expand its commercial and AI R&D hub in London. Nebius launched its first UK deployment of NVIDIA Blackwell Ultra infrastructure in November 2025. The three new sites will also deploy the latest generations of NVIDIA’s full-stack, end-to-end AI factory...
-
Pershing Square Holdings, Ltd. UK Regulatory Announcement: Transaction in Own Shares
LONDON--(BUSINESS WIRE)-- Pershing Square Holdings, Ltd. Announces Transactions in Own Shares - 5 June 2026 Pershing Square Holdings, Ltd. (LN:PSH) (LN:PSHD) (“PSH”) today announced that it has purchased, through PSH’s agent, Jefferies International Limited (“Jefferies”), the following number of PSH’s Public Shares of no par value (ISIN Code: GG00BPFJTF46) (the "Shares"): Total Buyback Ticker/s: PSH (LSE); PSHD (LSE) Date of Purchase: 5 June 2026 Number of Public Shares Purchased: 23,937 Sha...
-
La Conférence 2026 sur le développement du tourisme récepteur à Pékin s’ouvre et dévoile 10 nouvelles expériences touristiques pour les visiteurs internationaux
PÉKIN--(BUSINESS WIRE)--Du 1er au 6 juin 2026, la Conférence 2026 sur le développement du tourisme récepteur à Pékin s’est tenue dans la capitale chinoise. Coorganisé par le Bureau municipal de la culture et du tourisme de Pékin et le Bureau des échanges et de la coopération internationaux du ministère chinois de la Culture et du Tourisme, l’événement vise à enrichir l’offre touristique de Pékin, à stimuler la consommation culturelle et touristique et à renforcer l’attractivité internationale d...
-
2026 Beijing Inbound Tourism Development Conference Kicks off, Unveiling 10 New Inbound Tourism Experiences to Boost Cultural and Tourism Consumption
BEIJING--(BUSINESS WIRE)--From June 1–6, 2026, the 2026 Beijing Inbound Tourism Development Conference was held in Beijing, co-organized by the Beijing Municipal Bureau of Culture and Tourism and the Bureau of International Exchange and Cooperation of China’s Ministry of Culture and Tourism. Focusing on immersive experiences and real-world tourism resources, the event aims to enhance Beijing’s inbound tourism offerings, stimulate cultural and tourism consumption, and strengthen the city’s globa...
-
Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy
LJUBLJANA, Slovenia--(BUSINESS WIRE)--Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the lead...
-
ADOCIA annonce la présentation des données de phase 3 de THDB0206 (BioChaperone® Lispro) dans le diabète de type 2 lors des 86e sessions scientifiques de l'ADA, confirmant les résultats positifs déjà annoncés en juillet 2025
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris : FR0011184241 – ADOC), société biopharmaceutique au stade clinique spécialisée dans la recherche et le développement de solutions thérapeutiques innovantes pour le traitement du diabète et de l’obésité, annonce que les résultats complets de l'étude clinique de phase 3 (étude THDB0206L02, NCT05834868) menée en Chine auprès de personnes atteintes de diabète de type 2 avec BioChaperone® Lispro ont été présentés lors de la 86e...
-
ADOCIA Announces THDB0206 (BioChaperone® Lispro) Phase 3 Data in Type 2 Diabetes Presented at ADA 86th Scientific Sessions, Confirming the Positive Results Previously Announced in July 2025
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announces that the full results of the Phase 3 clinical study (Study THDB0206L02, NCT05834868) conducted on people with type 2 diabetes in China with BioChaperone® Lispro were presented at the American Diabetes Association (ADA) 86th Scientifi...
-
BitGo MENA、規制対象の電子取引を開始し、中東・北アフリカ(MENA)地域に包括的な取引サービスを提供
アラブ首長国連邦ドバイ&ニューヨーク--(BUSINESS WIRE)--(ビジネスワイヤ) -- デジタル資産のインフラ企業であるBitGo Holdings, Inc.(NYSE:BTGO)(以下「BitGo」)の子会社であるBitGo MENA FZE(以下「BitGo MENA」)は、中東・北アフリカ(MENA)地域における電子取引サービスの開始を発表しました。本サービスの開始により、顧客はBitGo MENAの確立された店頭取引(OTC)サービスと機関投資家向けレベルの電子執行機能を組み合わせた包括的な取引ソリューションを利用できるようになります。これらはすべて、ドバイの暗号資産規制当局(VARA)からBitGo MENAが取得したブローカー・ディーラー・ライセンスの下で運営されます。 今回のローンチにより、VARAの監督下にあるBitGo MENAの規制対象商品群がさらに拡充されることとなります。シームレスな執行やカストディ・ソリューションへの需要が高まるなか、同地域における機関投資家向けデジタル資産インフラの継続的な整備に向けた新たな一歩となります。 「中東・北アフリカ...